sodium fluoride F-18 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4488 22554-99-0

Description:

MoleculeDescription

Synonyms:

  • sodium fluoride F-18
  • sodium fluoride-18F
  • sodium fluoride (18F)
  • Molecular weight: 40.99
  • Formula: FNa
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 24, 1972 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Walking aid user 128.52 27.26 60 6890 35446 90586051
Prescribed underdose 116.01 27.26 72 6878 74947 90546550
Wound infection 99.85 27.26 75 6875 106327 90515170
Seronegative arthritis 92.30 27.26 39 6911 18195 90603302
Upper respiratory tract infection 83.42 27.26 73 6877 128245 90493252
Spinal fusion surgery 78.32 27.26 31 6919 12252 90609245
Visual impairment 71.73 27.26 68 6882 132297 90489200
Joint dislocation 61.90 27.26 40 6910 44542 90576955
Spondylitis 60.86 27.26 27 6923 14151 90607346
Type 2 diabetes mellitus 60.26 27.26 76 6874 203168 90418329
Lupus vulgaris 59.07 27.26 39 6911 45020 90576477
Osteoporosis 56.92 27.26 52 6898 96479 90525018
Retinitis 54.61 27.26 35 6915 38423 90583074
Laryngitis 50.29 27.26 37 6913 50716 90570781
Hepatic cirrhosis 49.33 27.26 40 6910 63213 90558284
Wheezing 48.04 27.26 74 6876 238006 90383491
Lupus-like syndrome 47.03 27.26 35 6915 48811 90572686
Anti-cyclic citrullinated peptide antibody 46.83 27.26 28 6922 27193 90594304
Adjustment disorder with depressed mood 46.62 27.26 37 6913 56716 90564781
Foot deformity 45.00 27.26 37 6913 59614 90561883
Dislocation of vertebra 44.93 27.26 36 6914 55932 90565565
Joint stiffness 43.97 27.26 41 6909 78001 90543496
Drug ineffective 42.65 27.26 27 6923 1384271 89237226
Exostosis 40.16 27.26 33 6917 53101 90568396
Grip strength decreased 38.08 27.26 41 6909 92535 90528962
Prescribed overdose 38.00 27.26 42 6908 97583 90523914
Deep vein thrombosis postoperative 37.59 27.26 36 6914 70773 90550724
Hip arthroplasty 37.20 27.26 37 6913 76171 90545326
Osteoarthritis 36.91 27.26 59 6891 195671 90425826
Wound 36.32 27.26 75 6875 302905 90318592
Bone erosion 36.09 27.26 31 6919 52990 90568507
Liver function test increased 35.64 27.26 38 6912 84817 90536680
Red blood cell sedimentation rate increased 34.71 27.26 37 6913 82558 90538939
Oedema 34.56 27.26 58 6892 200237 90421260
Disability 34.39 27.26 27 6923 40718 90580779
Urticaria 33.54 27.26 74 6876 312660 90308837
Sciatica 33.37 27.26 40 6910 101342 90520155
Lower limb fracture 32.10 27.26 36 6914 84977 90536520
Autoimmune disorder 31.58 27.26 34 6916 76710 90544787
Delirium 30.84 27.26 39 6911 104320 90517177
Ear infection 30.63 27.26 32 6918 69743 90551754
Gait inability 30.18 27.26 46 6904 146410 90475087
Weight increased 30.16 27.26 85 6865 417842 90203655
Pulmonary fibrosis 29.92 27.26 39 6911 107464 90514033
Hypercholesterolaemia 28.70 27.26 37 6913 100855 90520642
Road traffic accident 28.34 27.26 38 6912 107588 90513909
Fibromyalgia 28.23 27.26 54 6896 206215 90415282
Swollen joint count increased 27.37 27.26 38 6912 111168 90510329
Breast cancer stage III 27.26 27.26 33 6917 84414 90537083

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Respiratory tract infection bacterial 129.21 39.85 22 498 1887 42618928
Respiratory tract infection viral 122.83 39.85 23 497 3383 42617432
Fibrin D dimer increased 79.10 39.85 17 503 4968 42615847
Respiratory tract infection 76.07 39.85 23 497 26299 42594516
Cytokine release syndrome 71.86 39.85 25 495 44502 42576313

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Respiratory tract infection bacterial 102.34 23.46 22 3537 2394 110583346
Respiratory tract infection viral 87.68 23.46 23 3536 5855 110579885
Fibrin D dimer increased 51.06 23.46 17 3542 9828 110575912
Cytokine release syndrome 44.80 23.46 28 3531 70278 110515462
Respiratory tract infection 34.61 23.46 24 3535 71593 110514147
Seronegative arthritis 31.94 23.46 13 3546 13164 110572576
Vertebral lateral recess stenosis 31.65 23.46 6 3553 346 110585394
Ligamentum flavum hypertrophy 31.27 23.46 6 3553 369 110585371
Osteoarthropathy 31.21 23.46 6 3553 373 110585367
Spinal fusion surgery 25.55 23.46 10 3549 9146 110576594
Toe operation 25.32 23.46 6 3553 1008 110584732

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V09IX06 VARIOUS
DIAGNOSTIC RADIOPHARMACEUTICALS
TUMOUR DETECTION
Other diagnostic radiopharmaceuticals for tumour detection
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

V09IX Other diagnostic radiopharmaceuticals for tumour detection 10 drugs
fluciclovine (18F)fludeoxyglucose (18F)fluorodopa (18F)fluoroestradiol F 18fluoroethylcholine (18F)gallium (68Ga) edotreotidegallium (68Ga) gozetotideiobenguane (123I)iobenguane (131I)methionine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
CHEBI:749312 CHEBI
CHEMBL1200744 ChEMBL_ID
9L75099X6R UNII
1311495 RXNORM
235955 MMSL
26952 MMSL
d07542 MMSL
018450 NDDF
C0304965 UMLSCUI
23690531 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sodium FluorideF 18 HUMAN PRESCRIPTION DRUG LABEL 1 13267-542 INJECTION 600 mCi INTRAVENOUS ANDA 17 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 24562-002 INJECTION, SOLUTION 200 mCi INTRAVENOUS ANDA 25 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 40028-512 INJECTION, SOLUTION 200 mCi INTRAVENOUS ANDA 24 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 49609-102 INJECTION 200 mCi INTRAVENOUS ANDA 25 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 52670-550 INJECTION 91.50 mCi INTRAVENOUS ANDA 23 sections
Sodium FluorideF 18 HUMAN PRESCRIPTION DRUG LABEL 1 52768-125 INJECTION 200 mCi INTRAVENOUS ANDA 26 sections
Sodium FluorideF 18 HUMAN PRESCRIPTION DRUG LABEL 1 62072-500 INJECTION 200 mCi INTRAVENOUS ANDA 6 sections
Sodium FluorideF18 HUMAN PRESCRIPTION DRUG LABEL 1 65857-300 INJECTION 200 mCi INTRAVENOUS ANDA 24 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 67939-020 INJECTION 200 mCi INTRAVENOUS ANDA 24 sections
Sodium FluorideF 18 F 18 HUMAN PRESCRIPTION DRUG LABEL 1 76167-002 INJECTION 200 mg INTRAVENOUS unapproved drug other 25 sections
Sodium Fluoride F 18 HUMAN PRESCRIPTION DRUG LABEL 1 76451-018 INJECTION 200 mCi INTRAVENOUS ANDA 25 sections
Sodium FluorideF 18 HUMAN PRESCRIPTION DRUG LABEL 1 81759-002 INJECTION 200 mCi INTRAVENOUS ANDA 17 sections